5-HT1a receptor subtype agonist

• US 7,053,092 B2
• Filed: 01/28/2002
• Issued: 05/30/2006
• Est. Priority Date: 01/29/2001
• Status: Expired due to Term

• Current Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Original Assignee: Otsuka Pharmaceutical Company Limited (Otsuka Holdings Company Limited)
• Inventors: Kikuchi, Tetsuro, Tottori, Katsura, Uwahodo, Yasufumi, Hirose, Tsuyoshi, Jordon, Shaun
• Primary Examiner(s): SPIVACK, PHYLLIS G
• Application Number:
  US10/055,915
• Publication Number:
  US 20020173513A1
• Time in Patent Office: 1,583 Days
• Field of Search: 514/253.07
• US Class Current: 514/253.07
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4704 2-Quinolinones, e.g. carbostyril
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 1/08 for nausea, cinetosis or vertigo; Antiemetics
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT_1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1):
wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.

Claims

1. A method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT_1A receptor subtype wherein the disorder is depression selected from the group consisting of endogenous depression, major depression, melancholia and treatment resistant depression, which comprises administering to said patient a therapeutically effective amount of a carbostyril compound of formula (1), or a pharmaceutically acceptable salt or solvate thereof, wherein said patient is a mammal:

wherein the carbon-carbon bond between 3- and 4- positions in the carbostyril skeleton is a single or a double bond.

2. The method of claim 1 wherein the carbostyril compound is 7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxyl}-3,4-dihydrocarbostyril.